regulatory
confidence high
sentiment positive
materiality 0.65
Quoin Pharma receives FDA Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
Quoin Pharmaceuticals, Ltd.
- FDA granted Rare Pediatric Disease Designation (RPDD) on June 24, 2025 for QRX003.
- QRX003 is Quoin's lead asset for treating Netherton Syndrome, a rare genetic disorder.
- RPDD makes QRX003 eligible for priority review and a Rare Pediatric Disease Priority Review Voucher if approved.
- Quoin is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases.
- The designation underscores the unmet need in Netherton Syndrome with no approved therapies.
item 8.01